1.
Nooruddin Shaik. A Critical Review of Cinqair (Reslizumab) in the Treatment of Severe Asthma Patients. Fut J. Pharm & H. Sci [Internet]. 2023May3 [cited 2024Nov.16];3(2):126–133. Available from: https://pharmasprings.com/fjphs/article/view/442